Internal Medicine, Hematology & Oncology · Saint Louis, MO
NPI
1639589104
Since 2014
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
3015 N Ballas Rd
Saint Louis, MO, 63131
Phone (314) 996-5169
Groups this clinician bills Medicare through
Medicare paid, 2024
$88K
1,177 services
Medicare patients, 2024
393
Average age 76
Drug cost, 2024
$3.7M
2,110 prescriptions
Company payments, 2025
$359
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Matthew Stein was code 99214 (office e&m - established), 341 times for 196 patients. In total Matthew Stein billed 1,177 services in 20 codes, and Medicare paid $88K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-11-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 341 | 196 | $68.75 | $23K |
| 99215 Office E&M - Established | Facility | 272 | 90 | $102.58 | $28K |
| 99213 Office E&M - Established | Facility | 216 | 148 | $42.11 | $9,095 |
| 99233 Hospital E&M - Subsequent | Facility | 76 | 33 | $91.26 | $6,936 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 75 | 71 | $12.43 | $932 |
| 99223 Hospital E&M - Initial | Facility | 49 | 46 | $133.20 | $6,527 |
| 99204 Office E&M - New | Facility | 44 | 44 | $94.25 | $4,147 |
| 99205 Office E&M - New | Facility | 39 | 39 | $134.77 | $5,256 |
| 99232 Hospital E&M - Subsequent | Facility | 37 | 22 | $60.73 | $2,247 |
By year: 2022 $67K for 917 services; 2023 $85K for 1,078 services; 2024 $88K for 1,177 services.
Medicare prescription drug claims, 2024
In 2024, the drug Matthew Stein prescribed most often to Medicare patients was Anastrozole, with 291 prescriptions and refills. In total Matthew Stein wrote 2,110 Medicare prescriptions that cost $3.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 291 | 632 | 65 | $4,120 |
| Prednisone Generic | 130 | 157 | 37 | $531 |
| Tamoxifen Citrate Generic | 119 | 188 | 23 | $2,104 |
| Acyclovir Generic | 98 | 176 | 28 | $1,035 |
| Prochlorperazine Maleate Generic | 93 | 93 | 68 | $2,316 |
| Dexamethasone Generic | 87 | 89 | 44 | $932 |
| Gabapentin Generic | 87 | 109 | 22 | $835 |
| Hydroxyurea Generic | 71 | 187 | 19 | $2,057 |
| Ondansetron Hcl Generic | 62 | 63 | 41 | $364 |
| Ciprofloxacin Hcl Generic | 45 | 47 | 23 | $431 |
| Eliquis Apixaban | 42 | 88 | 13 | $51K |
| Oxycodone Hcl Generic | 40 | 40 | 12 | $376 |
| Revlimid Lenalidomide | 40 | 40 | Under 11 | $690K |
| Xarelto Rivaroxaban | 40 | 90 | Under 11 | $49K |
| Levothyroxine Sodium Generic | 33 | 69 | Under 11 | $505 |
Brand drugs: 372 claims; generic drugs: 1,738 claims; opioid claims: 108.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Matthew Stein $359 ($359 in general payments such as food, travel and fees) from 11 companies. The largest payer was E.R. Squibb & Sons, L.L.C. with $84.79.
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. BMY | 4 | $84.79 |
| Abbvie Inc. ABBV | 3 | $58.77 |
| Geron Corporation GERN | 2 | $44.06 |
| GlaxoSmithKline, LLC. GSK | 1 | $29.8 |
| Merck Sharp & Dohme LLC MRK | 1 | $27.2 |
| Pfizer Inc. PFE | 1 | $24.01 |
| Servier Pharmaceuticals LLC | 1 | $20.65 |
| Janssen Biotech, Inc. JNJ | 1 | $19.11 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 1 | $17.77 |
| EMD Serono, Inc. MRK.DE | 1 | $17.37 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.